Effects of pill burden on discontinuation of the initial HAART regimen in minority female patients prescribed 1 pill/day versus any other pill burden

References

• Airoldi, M., Zaccarelli, M., Bisi, L., Bini, T., Antinori, A., Mussini, C., … Maggiolo, F. (2010). One-pill once-a-day HAART: A simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Preference Adherence, 4, 115–125.
   PubMed Web of Science ®Google Scholar
• Bangsberg, D. R., Ragland, K., Monk, A., & Deeks, S. G. (2010). A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people. AIDS, 24, 2835–2840. doi:10.1097/QAD.0b013e328340a209
   PubMed Web of Science ®Google Scholar
• CDC. (2012). HIV in the United States: At a glance (p. 2). Centers for Disease Control. Retrieved from http://www.cdc.gov/hiv/statistics/basics/ataglance.html
   Google Scholar
• Chen, R. Y., Westfall, A. O., Mugavero, M. J., Cloud, G. A., Raper, J. L., Chatham, A. G., … Saag, M. S. (2003). Duration of highly active antiretroviral therapy regimens [Research support, non-U.S. gov't research support, U.S. gov't, P.H.S.]. Clinical Infectious Diseases, 37, 714–722. doi:10.1086/377271
   PubMed Web of Science ®Google Scholar
• El-Sadr, W. M., Lundgren, J. D., Neaton, J. D., Gordin, F., Abrams, D., Arduino, R. C., … Rappoport, C. (2006). CD4+ count-guided interruption of antiretroviral treatment [Comparative study multicenter study randomized controlled trial research support, N.I.H., extramural]. The New England Journal of Medicine, 355, 2283–2296. doi:10.1056/NEJMoa062360
   PubMed Web of Science ®Google Scholar
• Hammer, S. M., Saag, M. S., Schechter, M., Montaner, J. S., Schooley, R. T., Jacobsen, D. M., … Volberding, P. A. (2006). Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel [Practice guideline research support, non-U.S. gov't]. Journal of the American Medical Association, 296, 827–843. doi:10.1001/jama.296.7.827
   PubMed Web of Science ®Google Scholar
• Hill, S., & Kavookjian, J. (2012). Motivational interviewing as a behavioral intervention to increase HAART adherence in patients who are HIV+: A systematic review of the literature. AIDS Care, 24, 583–592. doi:10.1080/09540121.2011.630354
   PubMed Web of Science ®Google Scholar
• Hodder, S. L., Mounzer, K., DeJesus, E., Ebrahimi, R., Grimm, K., Esker, S., … Flaherty, J. F. (2010). Patient-reported outcomes in virologically suppressed, HIV-1–infected subjects after switching to a simplified, single-tablet regimen of Efavirenz, Emtricitabine, and Tenofovir DF. AIDS Patient Care and STDs, 24, 87–96. doi:10.1089/apc.2009.0259
   PubMed Web of Science ®Google Scholar
• Hogg, R. S., Yip, B., Chan, K. J., Wood, E., Craib, K. J., O'Shaughnessy, M. V., & Montaner, J. S. (2001). Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy [Research support, non-U.S. gov't]. Journal of the American Medical Association, 286, 2568–2577. doi:10.1001/jama.286.20.2568
   PubMed Web of Science ®Google Scholar
• Krueger, K. P., Berger, B. A., & Felkey, B. (2005) Medication adherence and persistence: A comprehensive review. Advances in Therapy, 22, 313–356. doi:10.1007/BF02850081
   PubMed Web of Science ®Google Scholar
• Long, L., Fox, M., Sanne, I., & Rosen, S. (2010). The high cost of second-line antiretroviral therapy for HIV/AIDS in South Africa [Research support, U.S. gov't, non-P.H.S.]. AIDS, 24, 915–919. doi:10.1097/QAD.0b013e3283360976
   PubMed Web of Science ®Google Scholar
• Maggiolo, F., Ravasio, L., Ripamonti, D., Gregis, G., Quinzan, G., Arici, C., … Suter, F. (2005). Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clinical Infectious Diseases, 40, 158–163. doi:10.1086/426595
   PubMed Web of Science ®Google Scholar
• Morin, N., Cherry, E., Li, X., & Wainberg, M. A. (1998). Cotransfection of mutated forms of human immunodeficiency virus type 1 Gag-Pol with wild-type constructs can interfere with processing and viral replication [Research support, non-U.S. gov't]. Journal of Human Virology, 1, 240–247.
   PubMedGoogle Scholar
• Ortego, C., Huedo-Medina, T. B., Llorca, J., Sevilla, L., Santos, P., Rodriguez, E., … Vejo, J. (2011). Adherence to highly active antiretroviral therapy (HAART): A meta-analysis. AIDS and Behavior, 15, 1381–1396. doi:10.1007/s10461-011-9942-x
   PubMed Web of Science ®Google Scholar
• Palella, Jr., F. J., Chmiel, J. S., Moorman, A. C., & Holmberg, S. D. (2002). Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients. AIDS, 16, 1617–1626. doi:10.1097/00002030-200208160-00007
   PubMed Web of Science ®Google Scholar
• Puskas, C. M., Forrest, J. I., Parashar, S., Salters, K. A., Cescon, A. M., Kaida, A., … Hogg, R. S. (2011). Women and vulnerability to HAART non-adherence: A literature review of treatment adherence by gender from 2000 to 2011. Current HIV/AIDS Reports, 8, 277–287. doi:10.1007/s11904-011-0098-0
   PubMedGoogle Scholar
• Rickles, N. M., Brown, T. A., McGivney, M. S., Snyder, M. E., & White, K. A. (2010) Adherence: A review of education, research, practice, and policy in the United States. Pharmacy Practice, 8(1), 1–17.
   Google Scholar
• Ruiz, L., Paredes, R., Gomez, G., Romeu, J., Domingo, P., Perez-Alvarez, N., … Clotet, B. (2007). Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients [Multicenter study randomized controlled trial research support, Non-U.S. gov't]. AIDS, 21, 169–178. doi:10.1097/QAD.0b013e328011033a
   PubMed Web of Science ®Google Scholar
• Wainberg, M. A. (1998). Global perspective from International AIDS Society president Mark Wainberg. Interview by Dennis Blakesley [Interview]. Journal of the American Medical Association, 280, 1811, 1813–1814.
   Web of Science ®Google Scholar
• WHO. (2010). Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach. Geneva: Author.
   Google Scholar
• Willig, J. H., Abroms, S., Westfall, A. O., Routman, J., Adusumilli, S., Varshney, M., … Mugavero, M. J. (2008). Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy [Research support, N.I.H., extramural research support, non-U.S. gov't]. AIDS, 22, 1951–1960. doi:10.1097/QAD.0b013e32830efd79
   PubMed Web of Science ®Google Scholar
• Yuan, Y., L'Italien, G., Mukherjee, J., & Iloeje, U. H. (2006). Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort. HIV Medicine, 7, 156–162. doi:10.1111/j.1468-1293.2006.00355.x
   PubMed Web of Science ®Google Scholar